Aquestive Therapeutics, Inc. AQST Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost.
The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Aquestive Therapeutics, Inc. (AQST) reported deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost of $2.97M in Q4 2025.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost has grown at a -32.6% compound annual growth rate (CAGR), from $6.53M to $2.97M.